Effect of sevoflurane on the inflammatory response during cardiopulmonary bypass in cardiac surgery: the study protocol for a randomized controlled trial
| Autor: | Mario Hiroyuki Hirata, Jéssica Bassani Borges, Gudrun Kunst, Caetano Nigro Neto, Carlos Gustavo dos Santos Silva, José de Ribamar Costa Júnior, Thiago Augusto Azevedo Maranhão Cardoso, Gisele Medeiros Bastos |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Inflammatory response Medicine (miscellaneous) 030204 cardiovascular system & hematology Sevoflurane law.invention Systemic inflammatory response 03 medical and health sciences Study Protocol 0302 clinical medicine Randomized controlled trial 030202 anesthesiology law Cardiopulmonary bypass medicine Clinical endpoint Humans Pharmacology (medical) Cardiac Surgical Procedures Coronary Artery Bypass CIRCULAÇÃO EXTRACORPÓREA Randomized Controlled Trials as Topic lcsh:R5-920 Cardiopulmonary Bypass business.industry Cardiac surgery Intensive care unit medicine.anatomical_structure Cardiac anesthesia Anesthesia Anesthetics Inhalation business lcsh:Medicine (General) medicine.drug Artery Volatile anesthetics |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP Trials Trials, Vol 22, Iss 1, Pp 1-10 (2021) |
| Popis: | Background Recent experimental evidence shows that sevoflurane can reduce the inflammatory response during cardiac surgery with cardiopulmonary bypass. However, this observation so far has not been assessed in an adequately powered randomized controlled trial. Methods We plan to include one hundred patients undergoing elective coronary artery bypass graft with cardiopulmonary bypass who will be randomized to receive either volatile anesthetics during cardiopulmonary bypass or total intravenous anesthesia. The primary endpoint of the study is to assess the inflammatory response during cardiopulmonary bypass by measuring PMN-elastase serum levels. Secondary endpoints include serum levels of other pro-inflammatory markers (IL-1β, IL-6, IL-8, TNFα), anti-inflammatory cytokines (TGFβ and IL-10), and microRNA expression in peripheral blood to achieve possible epigenetic mechanisms in this process. In addition clinical endpoints such as presence of major complications in the postoperative period and length of hospital and intensive care unit stay will be assessed. Discussion The trial may determine whether adding volatile anesthetic during cardiopulmonary bypass will attenuate the inflammatory response. Trial registration ClinicalTrials.gov NCT02672345. Registered on February 2016 and updated on June 2020. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|